Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.

Impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis versus non-rheumatoid arthritis subjects: results from a population-based study.

Myasoedova E, Gabriel SE, Green AB, Matteson EL, Crowson CS.

Arthritis Care Res (Hoboken). 2013 Oct;65(10):1592-9. doi: 10.1002/acr.22029.

2.

Total cholesterol and LDL levels decrease before rheumatoid arthritis.

Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE.

Ann Rheum Dis. 2010 Jul;69(7):1310-4. doi: 10.1136/ard.2009.122374. Epub 2009 Oct 23.

3.

Statins and Risk of Rheumatoid Arthritis: A Nested Case-Control Study.

Tascilar K, Dell'Aniello S, Hudson M, Suissa S.

Arthritis Rheumatol. 2016 Nov;68(11):2603-2611. doi: 10.1002/art.39774.

4.

Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.

Liao KP, Liu J, Lu B, Solomon DH, Kim SC.

Arthritis Rheumatol. 2015 May;67(8):2004-10. doi: 10.1002/art.39165.

5.

Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.

Curtis JR, John A, Baser O.

Arthritis Care Res (Hoboken). 2012 Sep;64(9):1282-91. doi: 10.1002/acr.21693.

7.

Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment.

Akiyama M, Mawatari T, Nakashima Y, Miyahara H, Yamada H, Okazaki K, Fukushi J, Kondo M, Kishimoto J, Hashimura C, Iwamoto Y.

Clin Rheumatol. 2015 Nov;34(11):1867-75. doi: 10.1007/s10067-015-3049-0. Epub 2015 Aug 21.

PMID:
26292631
8.

Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings.

O'Connor PJ, Gray RJ, Maciosek MV, Fillbrandt KM, DeFor TA, Alexander CM, Weiss TW, Teutsch SM.

Prev Chronic Dis. 2005 Jul;2(3):A05. Epub 2005 Jun 15.

9.
10.

Cardiovascular Outcomes Associated with Lowering Low-density Lipoprotein Cholesterol in Rheumatoid Arthritis and Matched Nonrheumatoid Arthritis.

An J, Alemao E, Reynolds K, Kawabata H, Solomon DH, Liao KP, Niu F, Cheetham TC.

J Rheumatol. 2016 Nov;43(11):1989-1996. Epub 2016 Sep 1.

PMID:
27585690
11.

Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention.

Rollefstad S, Ikdahl E, Hisdal J, Kvien TK, Pedersen TR, Holme I, Semb AG.

Ann Rheum Dis. 2015 Aug;74(8):1544-50. doi: 10.1136/annrheumdis-2013-204636. Epub 2014 Apr 3.

PMID:
24699940
12.

Atheroma progression in hyporesponders to statin therapy.

Kataoka Y, St John J, Wolski K, Uno K, Puri R, Tuzcu EM, Nissen SE, Nicholls SJ.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):990-5. doi: 10.1161/ATVBAHA.114.304477. Epub 2015 Feb 26.

13.

Outcome of rheumatoid arthritis following adjunct statin therapy.

Das S, Mohanty M, Padhan P.

Indian J Pharmacol. 2015 Nov-Dec;47(6):605-9. doi: 10.4103/0253-7613.169585.

14.

Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).

Spinler SA, Cziraky MJ, Willey VJ, Tang F, Maddox TM, Thomas T, Dueñas GG, Virani SS; NCDR.

Am J Cardiol. 2015 Aug 15;116(4):547-53. doi: 10.1016/j.amjcard.2015.05.011. Epub 2015 May 21.

PMID:
26089010
15.

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.

Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE.

Ann Rheum Dis. 2011 Mar;70(3):482-7. doi: 10.1136/ard.2010.135871. Epub 2011 Jan 7.

16.

Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients.

Munkhaugen J, Sverre E, Otterstad JE, Peersen K, Gjertsen E, Perk J, Gullestad L, Moum T, Dammen T, Husebye E.

Eur J Prev Cardiol. 2017 Jun;24(9):981-989. doi: 10.1177/2047487317693134. Epub 2017 Feb 14.

PMID:
28196429
17.

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.

Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Jünger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ; DYSIS Investigators.

Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10.

PMID:
21450578
18.

Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population.

Liao KP, Cai T, Gainer VS, Cagan A, Murphy SN, Liu C, Churchill S, Shaw SY, Kohane I, Solomon DH, Plenge RM, Karlson EW.

Arthritis Care Res (Hoboken). 2013 Dec;65(12):2046-50. doi: 10.1002/acr.22091.

19.

Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism.

Delluc A, Malécot JM, Kerspern H, Nowak E, Carre JL, Mottier D, Le Gal G, Lacut K.

Atherosclerosis. 2012 Jan;220(1):184-8. doi: 10.1016/j.atherosclerosis.2011.10.007. Epub 2011 Oct 14.

PMID:
22035572
20.

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study.

Azar ST, Hantash HA, Jambart S, El-Zaheri MM, Rachoin R, Chalfoun A, Lahoud L, Okkeh O, Bramlage P, Brudi P, Ambegaonkar BM.

Vasc Health Risk Manag. 2014 May 7;10:225-35. doi: 10.2147/VHRM.S57194. eCollection 2014.

Supplemental Content

Support Center